Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

99.85 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Jan 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
98 99 Next >
5 Stocks Powering The Dow ETF Year To Date
While most of the stocks in the ETF portfolio have been rising this year, these five that have been leading the way higher. 
Via Talk Markets
Topics ETFs Stocks
Exposures US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Storm Shelter: 7 Safe Haven Stocks to Batten Down the Hatches
With the market potentially posing some challenges, investors may find comfort in considering these safe haven stocks to buy. 
Via InvestorPlace
Which Is The Best Investment For You? High Yield Pfizer Or Higher Growth Merck?
It depends on what your goals, objectives, and risk tolerances are. 
Via Talk Markets
Check Out What Whales Are Doing With MRK
Via Benzinga
Market Analysis: Merck &amp; Co And Competitors In Pharmaceuticals Industry
Via Benzinga
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France,... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
From Merck & Co., Inc.
Via Business Wire
Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma Treatment
Merck halts vibostolimab and pembrolizumab coformulation arm in KeyVibe-010 Phase 3 trial for high-risk melanoma due to higher discontinuation rates and immune-related adverse events. 
Via Benzinga
Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
From Merck & Co., Inc.
Via Business Wire
Healthcare And Biotech Investing 101: What You Need To Know.
Healthcare as a sector represents only about 12% of the S&P 500. If you want to overweight healthcare as a sector you need to add equities. Healthcare is usually a defensive sector because of... 
Via Talk Markets
Topics Stocks
Exposures US Equities
What's Going On With Medical Therapeutic Firm Aethlon Medical On Friday?
Aethlon Medical unveils results in removing extracellular vesicles (EVs) from plasma. Preclinical evidence supports upcoming phase 1 trials for solid tumor patients undergoing anti-PD-1 monotherapy. 
Via Benzinga
3 Biotech Stocks to Sell in May Before They Crash & Burn
Discover essential insights on biotech stocks to sell in May to navigate market volatility and safeguard your investment portfolio. 
Via InvestorPlace
The 3 Most Undervalued Healthcare Stocks to Buy in May 2024
These are the undervalued healthcare stocks to buy as they represent companies with steady growth visibility. 
Via InvestorPlace
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025
The second wave of the weight loss drug stock boom is underway and investors should heed the signs the market is serving. 
Via InvestorPlace
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
From Merck & Co., Inc.
Via Business Wire
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
EQNX::TICKER_START (OTCPK:MUSLF),(CSE:MUSL),(NYSE:MRK),(NYSE:PFE),(NASDAQ:MRNA),(NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
Merck to Participate in the Bank of America Securities 2024 Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Jim Cramer Advises Investors To Brace For Economic Slowdown, Shares Tips To Maintain Balanced Portfolio: 'I'm Not Telling You To Relax'
Jim Cramer, the host of CNBC's "Mad Money," has warned investors about the current state of the economy and suggested strategies to navigate the challenging period. 
Via Benzinga
Topics Economy
Exposures Economy
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
From FN Media Group LLC
Via GlobeNewswire
A Look At Pharma ETFs Post Q1 Earnings
Pharma ETFs have delivered mixed performances over the past month. 
Via Talk Markets
Topics ETFs
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Biotech Stocks to Double Your Money in the Next 24 Months
The biotech sector offers significant potential for growth. These 3 biotech stocks to double your money are noteworthy candidates. 
Via InvestorPlace
In a market where value is scarce, NYSE:MRK offers a refreshing opportunity with its solid fundamentals.
MERCK & CO. INC. (NYSE:MRK) stands out as a stock that provides good value for the fundamentals it showcases. 
Via Chartmill
Serum Institute of India Inks Large-Scale Supply Deal For BCG Use In ImmunityBio's Bladder Cancer Combo Therapy
Unlocking global access to Bacillus Calmette-Guerin (BCG) for cancer therapy. ImmunityBio partners with Serum Institute to expand BCG supply. FDA-approved Anktiva plus BCG for bladder cancer. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
After topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co Inc (NYSE: MRK) just reported encouraging data from its Phase III gastric cancer treatment trial after... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
From Merck & Co., Inc.
Via Business Wire
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
From Merck & Co., Inc.
Via Business Wire
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
98 99 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.